Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 14/20 | 0.50 |
| ▸ | CA2 | P00918 | 14/20 | 0.50 |
| ▸ | CA9 | Q16790 | 10/20 | 0.50 |
| ▸ | CA12 | O43570 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2359181 | 0.90 | KMT2A (0.43) | KMT2ACA1CA2CA9CA12 | |
| SCHEMBL2359845 | 0.81 | MEN1 (0.47) | KMT2AALDH1A1LMNAMAPTPOLB | |
| SCHEMBL2359771 | 0.80 | LMNA (0.44) | KMT2AALDH1A1LMNAMAPTPOLB | |
| SCHEMBL2359355 | 0.79 | FADS1 (0.43) | KMT2ACA2ALDH1A1LMNA | |
| SCHEMBL2361067 | 0.79 | LMNA (0.47) | KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL2360576 | 0.78 | LMNA (0.61) | KMT2AALDH1A1LMNAMAPTPOLB | |
| SCHEMBL12350716 | 0.77 | HSD11B1 (0.47) | KMT2ACA1CA2CA9CA12 | |
| SCHEMBL2360399 | 0.76 | HTT (0.47) | KMT2AALDH1A1LMNAALOX12MAPT | |
| SCHEMBL4296805 | 0.76 | CA1 (0.52) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL2361047 | 0.76 | EPHX2 (0.52) | ALDH1A1LMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011094953-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | claimed |
| WO-2011094953-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095576-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | NAT1, NHERF1, ADORA1 | KMT2A 2790/4885CA1 931/4885CA2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.